A 62-Year-Old Man Presents With Anemia & Fever

Poll

A 62-year-old man presents with anemia and fever. A renal mass is detected and a biopsy is performed. What is your diagnosis?

A 62-year-old man presents with anemia, fever, and a renal mass. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Sarcomatoid carcinoma
B. Clear cell carcinoma
C. Transitional cell carcinoma
D. Malakoplakia
Recent Videos
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content
The regulatory agency gave a PDUFA target action date of April 6. 2026 for Orca-T among patients with AML, ALL, and MDS.

FDA Grants Priority Review to BLA for Orca-T in Hematologic Malignancies

Roman Fabbricatore
October 6th 2025
Article

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Treatment discontinuation occurred in 9% of patients, of which 1% and 3% were caused by anemia and hypoxia, respectively.

Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer

Tim Cortese
October 6th 2025
Article

Casdatifan, administered at 100 mg once daily, achieved a confirmed ORR of 35% in patients with pretreated metastatic kidney cancer.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.